First-line treatment trials in elderly patients with MCL
| . | n . | CR % . | PFS . | OS . | Grade 3-4 neutropenia % . | Febrile neutropenia % . | Fatigue % . | Severe fatigue % . |
|---|---|---|---|---|---|---|---|---|
| R-CHOP21x827 | 239 | 34 | ND | 62% (4 y) | 60 | 17 | 58 | 6 |
| RB28 | 46 | 40 | 61% (4 y) | ND | 29 | ND | 16 | ND |
| RB29 | 36 | 50 | ND | ND | ND | ND | 44 | ND |
| VR-CAP30 | 243 | 53 | 24.7 mo (median) | 64% (4 y) | 85 | 15 | 23 | 6 |
| R-BAC31 | 20 | 95 | 95% (2 y) | 95% (2 y) | 17 | 12 | 35 | 5 |
| R-chlorambucil32 | 20 | 90 | 89% (3 y) | 95% (3 y) | ND | None | ND | ND |
| R-chlorambucil33 | 14 | 36 | 15 mo (median) | 26 mo (median) | 36 | ND | ND | ND |
| RiBVD36 | 74 | 74 | 70% at 2 y | ND | 51 | 5 | 19 | ND |
| Lenalidomide-rituximab37 | 38 | 64 | 85% (2 y) | 97% (2 y) | 50 | 5 | 74 | 8 |
| Ibrutinib38 | 139 | 72 | 41% (2 y) | 68% (1 y) | 13 | ND | 22 | 4 |
| . | n . | CR % . | PFS . | OS . | Grade 3-4 neutropenia % . | Febrile neutropenia % . | Fatigue % . | Severe fatigue % . |
|---|---|---|---|---|---|---|---|---|
| R-CHOP21x827 | 239 | 34 | ND | 62% (4 y) | 60 | 17 | 58 | 6 |
| RB28 | 46 | 40 | 61% (4 y) | ND | 29 | ND | 16 | ND |
| RB29 | 36 | 50 | ND | ND | ND | ND | 44 | ND |
| VR-CAP30 | 243 | 53 | 24.7 mo (median) | 64% (4 y) | 85 | 15 | 23 | 6 |
| R-BAC31 | 20 | 95 | 95% (2 y) | 95% (2 y) | 17 | 12 | 35 | 5 |
| R-chlorambucil32 | 20 | 90 | 89% (3 y) | 95% (3 y) | ND | None | ND | ND |
| R-chlorambucil33 | 14 | 36 | 15 mo (median) | 26 mo (median) | 36 | ND | ND | ND |
| RiBVD36 | 74 | 74 | 70% at 2 y | ND | 51 | 5 | 19 | ND |
| Lenalidomide-rituximab37 | 38 | 64 | 85% (2 y) | 97% (2 y) | 50 | 5 | 74 | 8 |
| Ibrutinib38 | 139 | 72 | 41% (2 y) | 68% (1 y) | 13 | ND | 22 | 4 |
ND, not determined; OS, overall survival; PFS, progression-free survival; RB, rituximab bendamustine.